# Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome

> **NCT04645446** · PHASE2 · COMPLETED · sponsor: **SIFI SpA** · enrollment: 96 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** Pro-ocular gel
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT04645446
- **Lead sponsor:** SIFI SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-18
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-10-27
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04645446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04645446, "Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04645446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*